09:23 EDT Ventyx falls 19% to $2.39 after Crohn’s disease trial misses endpoint
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx pullback an opportunity to accumulate shares, says Piper Sandler
- Ventyx Biosciences price target lowered to $10 from $12 at Oppenheimer
- Ventyx Biosciences announces positive pre-clinical data for VTX3232
- Ventyx Biosciences Reveals Promising Obesity Treatment Data
- Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Questions or Comments about the article? Write to editor@tipranks.com